Investigational drug · Phase 2
PM359
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Granulomatous Disease, Granulomatous Disease, Chronic.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "PM359"
First trial start
2024
Oct 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PM359", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Granulomatous Disease
- Granulomatous Disease, Chronic
Largest trials
Live from ClinicalTrials.gov: studies naming "PM359" as an intervention, largest first.
- A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )Enrolling by invitation
Prime Medicine, Inc.Industry
NCT06559176 · 12 participants (planned) · Start Oct 17, 2024 · Primary completion Jan 2030
Drug: PM359 · For: Chronic Granulomatous Disease; Granulomatous Disease, Chronic
Sites: Los Angeles, California; Bethesda, Maryland; Nashville, Tennessee · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Prime Editing and Its Delivery: Recent Advances in Gene Correction for Genetic Diseases.
Zhang S, Chang L, Kong Y, et al. · Curr Gene Ther 2026
- Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.
Gori JL, Haddad E, Frangoul H, et al. · N Engl J Med 2026
- Prime Editing: The Next Frontier in Precision Gene Therapy.
Aliciaslan M, Erbasan E, Erendor F, et al. · J Gene Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.